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Abstract
Background: Although the association of weight gain and developing metabolic syndrome (MetS)
has been reported in the Western and Asian populations, data on the gender-stratified effects of
weight change (including weight loss) on incident MetS and its components in the Middle East
Caucasians is still scarce.
Methods: A total of 1431 men and 2036 women aged ≥ 20 years with BMI > 18.5 kg/m2 were
followed over 3 years. Multivariate logistic regression analysis was used to estimate the relative risk
(RR) of MetS and its components (the Adult Treatment Panel III definition) associated with gender-
stratified quintiles of percent weight change. Subjects with MetS at baseline were excluded for
analyzing the RR of MetS.
Results: There was 20.4% (95% CI, 19.6–21.2) age-adjusted incident MetS (18.4% male vs. 23.1%
women). In men, mild weight gain (WG) predicted high waist circumference (WC) and high
triglyceride; moderate WG predicted MetS (RR 2.5, 95% CI 1.4–4.3), high WC and high blood
pressure (BP); large WG predicted MetS (RR 3.2, 95% CI 1.8–5.7) and its components, except for
high fasting plasma glucose. In women, mild WG predicted MetS (RR 2.5, 95% CI 1.4–4.3), high WC
and high BP; moderate WG predicted Mets (RR 4.6, 95% CI 2.7–8.0), high WC and high
triglyceride; large WG predicted MetS (RR 6.6, 95% CI 3.8–11.3) and its components except for
low HDL-cholesterol. Mild weight loss had protective effect on high WC in both genders and MetS
in men (RR 0.5, 95% CI 0.26–0.97, P = 0.04).
Conclusion: Weight change showed different effects on MetS in men and women. In women, mild
WG predicted MetS; however, mild weight loss was protective against MetS in men and high WC
in both genders.
Background
The prevalence of overweight and obesity is increasing
worldwide [1], and body weight is closely associated with
mortality and morbidity [2,3]. Obesity has been known as
an important risk factor of cardiovascular disease (CVD)
[4] and weight reduction in overweight or obese individ-
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uals was known to have beneficial health effects [5]. It has
been suggested that weight gain increases risk of develop-
ing hyperinsulinemia [6] and insulin resistance is an ori-
gin of metabolic syndrome (MetS) which is a strong risk
factor of CVD [7]. Therefore, it seems that investigations
on the association of weight change and MetS are essential
to clarify the relationship between weight change and
mortality.
Although self-reported weight gain is proven to be associ-
ated with the development of the MetS [8], only a few
studies have prospectively assessed the impact of docu-
mented weight gain on MetS or its components [6,9]. Fur-
thermore, not much published data is available about the
effect of weight loss on MetS and its components [6,10-
12].
On the other hand, body weight is a different entity
among men and women [13] and the association between
body mass index (BMI) and mortality was found to be dif-
ferent for men and women [14]. Therefore, to gain better
knowledge about the weight gain epidemic and its adverse
effect on MetS parameters, we believe that investigations
stratified by gender need to be conducted.
Considering the high prevalence of MetS and the rising
trend of obesity in our population [15,16], we examined
the impact of gender-stratified weight change on the risk
of incident MetS and its components in participants of the
Tehran Lipid and Glucose Study (TLGS) cohort during 3.1
years follow-up.
Subjects
This study was conducted within the framework of the
TLGS, a population based prospective study conducted on
residents of district 13 of Tehran, with the aim of deter-
mining the prevalence of noncommunicable disease-risk
factors and developing a healthy lifestyle to decrease these
risk factors [17]. In the TLGS, 15005 people aged 3 years
and over, living in district 13 of Tehran were selected by a
multistage cluster random sampling method; among
them, were 10368 subjects aged ≥ 20 years who partici-
pated in phase 1 (cross-sectional phase) from 1999–2001.
After this phase, subjects were entered to the two, the
cohort and the interventional groups. The cohort group
consisted of 6437 subjects aged ≥ 20 years and after
excluding those with BMI ≤ 18.5 kg/m2 (n = 339) at base-
line, 6098 subjects remained. From these, after further
excluding subjects with missing data (n = 112), death
events (n = 120) and loss to follow up (n = 2399), there
were 3467 subjects with full relevant data who underwent
the second examination in phase 2 until September 2005
and entered to the current study (participation rate
≈57%). The main reasons for non responders in the fol-
low up study were either migration (30%) or lack of con-
tribution. The Ethical Committee of The Endocrine
Research Center of Shahid Beheshti University (Medical
Campus) approved the proposal of this study. Informed
written consent was obtained from all subjects.
Methods
Subjects were interviewed privately, face-to-face, inter-
views being conducted by trained interviewers using pre-
tested questionnaires. Initially, information on age,
smoking habits, subjects' physical activity status, educa-
tion level and medication use for treatment of diabetes,
hypertension and lipid disorders was collected. Subjects
with current or past history of smoking were called smok-
ers and those who had never smoked were non smokers.
Physical activity was categorized to three groups; vigorous,
those who had hard physical activity (leisure time or occu-
pational) at least three times a week; moderate, those who
had hard physical activity at least once a week regularly;
none, those without any regular hard physical activity.
Education was categorized to three groups; Illiterate,
under diploma and higher than diploma. Weight was
measured, while subjects were minimally clothed without
shoes using digital scales and recorded to the nearest 100
g. Height was measured in a standing position, without
shoes, using tape stadimeter while shoulders were in a
normal position. BMI was calculated as weight in kilo-
grams divided by height in meters squared. Waist circum-
ference (WC) was measured at the umbilical level, using
unstretched tape meter, without any pressure to body sur-
face, and was recorded to the nearest 0.1 cm. To avoid
inter subjective error; all measurements were taken by the
same person. To measure blood pressure (BP), subjects
were first made to rest for 15 min, and then a qualified
physician measured BP twice, during physical examina-
tions in a seated position after one initial measurement
for determining the peak inflation level using a standard
mercury sphygmomanometer. There was at least a 30-sec-
ond interval between these two separate measurements,
and thereafter the mean of the two measurements was
considered as the participant's blood pressure. A blood
sample was taken after 12–14 hour overnight fasting.
Blood samples were taken in a sitting position according
to the standard protocol and centrifuged within 30–45
min of collection. All blood analyses were done at the
TLGS research laboratory on the day of blood collection.
Fasting plasma Glucose (FPG) was measured by the enzy-
matic colorimetric method using glucose oxidize. For
lipid measurements, triglyceride kit (Pars Azmoon Inc.,
Iran) was used. Triglyceride (TG) was assayed using enzy-
matic colorimetric tests with glycerol phosphate oxidize.
HDL cholesterol (HDL-C) was measured after precipita-
tion of the apolipoprotein B containing lipoproteins with
phosphotungistic acid. Lipid standard (C.f.a.s., Boe-
hringer Mannheim, Germany; cat. no. 759350) was used
to calibrate the selectra 2 auto-analyzer for each day ofBMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
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laboratory analyses. All samples were analyzed when
internal quality control met the acceptable criteria. Inter-
and intra assay coefficients of variation (CV) for TG were
less than 1.6% in the baseline, and less than 3.9% in the
follow-up examination, respectively. The equivalent CVs
for glucose were less than 2.2% at baseline, and less than
3.3% at follow-up examination, respectively. The method
for glucose and lipid measurement was the same at both
baseline and follow-up.
Definition of Terms
The MetS was defined according to the Adult Treatment
Panel III (ATPIII) guidelines as the presence of three or
more of the following [18]: (1) Abdominal obesity (high
WC) as WC > 102 cm for men and > 88 cm for women,
(2) High TG level (≥ 1.7 mmol/l); (3) Low HDL-C level (<
1.03 mmol/l in men and < 1.29 mmol/l in women);(4)
High BP [systolic blood pressure (SBP) ≥ 130 or diastolic
blood pressure (DBP) ≥ 85 mm Hg)]; (5) High FPG con-
centration (≥ 6.1 mmol/l).
Weight Change
Percentage of weight change (PWC) during the 3.1 year
follow-up was assessed in men and women of the study
population separately. PWC was calculated as: [(Weight at
phase 2 – Weight at phase1/Weight at phase1) × 100].
Based on the distribution of weight change among both
genders, the weight change percent was divided into quin-
tiles, which resulted in a relatively similar number of sub-
jects in each group as follows: Weight loss group [PWC <-
1.3% men (n = 294), <-2.5% women (n = 404)]; weight
stable (referent group) [PWC -1.3 to 1.3% men (n = 277),
-2.5 to 1.2% women (n = 412)]; mild weight gain group
[PWC 1.4 to 3.9% men (n = 298), 1.3 to 3.9% women (n
= 401)]; moderate weight gain group [PWC 4 to 6.9%
men (n = 266), 4 to 7.6% women (n = 391)]; large weight
gain group [PWC ≥ 7% men (n = 296), ≥7.7% women (n
= 428)].
Data Analysis
All data were analyzed by SPSS software package (SPSS
Inc., Chicago, IL, USA; Version 15). Mean (SD) values or
frequency (percentage) of baseline characteristics were
expressed. The means and percents of the individual vari-
ables were compared between baseline and follow-up
groups, by using paired t-test and McNemar test, respec-
tively. General Linear Model was used to estimate means
of individual MetS parameters at the 3.1 year follow up
examination according to 5 PWC groups adjusted for age,
baseline weight, smoking status, physical activity, educa-
tion level, medication use for treatment of diabetes,
hypertension and lipid disorders and the corresponding
parameter, at baseline. To elucidate the difference and
similarity of the effects of PWC according to gender, sub-
jects were stratified into 2 groups by gender. For MetS and
each of its components, relative risk (RR) and the 95%
confidence intervals (CI) according to the gender-strati-
fied quintiles of PWC were calculated after adjustments of
age, baseline weight, smoking status, physical activity,
education level and medication use for treatment of dia-
betes, hypertension and lipid disorders. The second quin-
tile of PWC, which was called the stable group, was
considered as the reference. To examine the RR of devel-
oping MetS and its components, logistic models were fit-
ted separately in subject who did not have MetS or its
components at baseline, respectively.
Results
In comparison to the subjects who did not attend the fol-
low-up visit, those who attended had higher values of age
(44. vs. 40.8 years), BMI (27. 3 vs. 26.5 kg/m2), WC (89.2
vs. 87 cm), SBP (120.8 vs. 118.9 mmHg), DBP (78. 6 vs.
77.5 mmHg), FPG (5.5 vs. 5.4 mmol/l), TG (2 vs. 1.8
mmol/l), (all p values < 0.05). However, there was no dif-
ference in HDL-C levels between participants vs. nonpar-
ticipants.
The current analysis included 3467 subjects (1431 male
and 2036 female, sex ratio M: W = 0.7) with a mean (SD)
age of 44.4 (14.2) years. At baseline, the average BMI was
27.3 (4.4) kg/m2, normally distributed. Also, 31.9% of the
total participants had normal weight (BMI 18.5–24.99 kg/
m2), 42.5% were overweight (BMI 25–29.99 kg/m2) and
25.6% were obese (BMI ≥ 30 kg/m2). After a mean 3.1
years of follow-up, range of 9 months to 6 years, the
cohort gained a mean weight of 1.9 kg with a range of -28
to +39 kg of weight change, and the prevalence of over-
weight and obesity increased to 43.3% and 31.3%, respec-
tively (Data not shown). As shown in Table 1 all of the
anthropometric and metabolic parameters were higher
after follow-up except serum TG levels, HDL-C, SBP and
DBP. Medication use for dyslipidemia in males and for
hypertension and diabetes in both genders were more
prevalent at follow-up. There were more smokers in both
genders after follow-up. At baseline, 26% of participants
had vigorous and 59.9% had low physical activity. Also,
10.7% of study population was illiterate and 77.7% of
those had under diploma education. Among men, we
found 394 subjects with MetS at baseline and 484 MetS
cases at the follow up; however from the latter, 274 sub-
jects overlapped with baseline cases, with 210 new cases
of MetS remained. Among women, we found 856 subjects
with MetS at baseline and 969 MetS cases at the follow up,
of which 699 subjects overlapped with baseline cases,
hence 270 new cases of MetS remained. Therefore, from
among the 2217 participants free of MetS at baseline we
had 480 (210 men and 270 women) new cases of MetS
during 3.1 years follow up. The age-adjusted (Iran census,
2006) incidence of MetS was 20.4% (95% CI, 19.6–21.2)
in the total population. Incident MetS was found to beBMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
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Table 1: General characteristic of the study participants at the baseline examination and follow-up by gender*
Men (n = 1431) Women (n = 2036)
General characteristics At baseline At follow-up P value At baseline At follow-up P value
Age (year) 45.7 ± 14.9 48.9 ± 14.8 < 0.001 43.5 ± 13.6 46.8 ± 13.6 < 0.001
Weight (kg) 75.4 ± 12.3 77.6 ± 12.7 < 0.001 68.8 ± 11.8 70.5 ± 12.0 < 0.001
BMI (kg/m2) 26.2 ± 3.8 26.8 ± 3.9 < 0.001 28.1 ± 4.6 29.1 ± 4.8 < 0.001
WC (cm) 89.8 ± 10.8 95.4 ± 10.3 < 0.001 89 ± 12.2 92.8 ± 12.3 < 0.001
FPG (mmol/l) 5.4 ± 1.5 5.6 ± 1.7 < 0.001 5.6 ± 2.1 5.7 ± 2.2 < 0.001
Triglyceride (mmol/l) 2.1 ± 1.4 2 ± 1.3 < 0.001 1.9 ± 1.2 1.8 ± 1.2 < 0.001
HDL-C (mmol/l) 1.0 ± 0.2 0.9 ± 0.2 < 0.001 1.2 ± 0.3 1 ± 0.2 < 0.001
SBP (mmHg) 122.3 ± 19.1 120.2 ± 18.5 < 000.1 119.9 ± 19.4 118.2 ± 20.1 < 0.001
DBP (mmHg) 78.6 ± 11.0 75.7 ± 11.1 < 0.001 78.6 ± 10.3 75.8 ± 10.1 < 0.001
ATPIII MetS, no (%) 394 (27.5) 484 (33.8) < 0.001 856 (42) 969 (47.6) < 0.001
Smokers, no (%) 574 (40.4) 628 (44.2) < 0.001 111 (5.5) 138 (6.8) < 0.001
Medication for, no (%)
Dyslipidemia 31 (2.2) 43 (3.0) < 0.001 111 (5.5) 101 (5.0) < 0.001
Hypertension 94 (6.6) 95 (6.7) < 0.001 235 (11.6) 270 (13.3) < 0.001
Diabetes 39 (2.7) 68 (4.8) < 0.001 109 (5.4) 158 (7.8) < 0.001
* Plus, minus represents mean ± standard deviation
BMI: body mass index, WC: waist circumference, FPG: fasting plasma glucose, SBP: systolic blood pressure, DBP: diastolic blood pressure
Smokers are those with current or past history of smoking.
ATPIII defined Mets: metabolic syndrome by the ATPIII definition which is indicated in reference 18.
Table 2: Adjusted means of the metabolic physiological parameters by weight change groups after 3 years follow-up*
Gender-stratified percentage of weight change†
Metabolic 
parameters
Loss group 
(294 M; 404 W)
Stable group 
(277 M; 412 W)
Mild gain group 
(298 M; 401 W)
Moderate gain group 
(266 M; 391 W)
Large gain group 
(296 M; 428 W)
P value
Men (n = 1431)
WC (cm) 90.8 (0.5) 93.7 (0.5) 95.3 (0.5) 96.8 (0.5) 100.5 (0.5) < 0.001
TG (mmol/l) 1.9 (0.1) 2 (0.1) 2.2 (0.1) 2.3 (0.1) 2.6 (0.1) < 0.001
FPG (mmol/l) 6.9 (0.2) 6.8 (0.2) 6.9 (0.2) 6.9 (0.2) 6.9 (0.2) 0.7
HDL-C 
(mmol/l)
0.88 (0.02) 0.85 (0.02) 0.86 (0.02) 0.83 (0.02) 0.080 (0.02) 0.001
SBP (mmHg) 119.8 (1.7) 121.9 (1.8) 123.5 (1.8) 124.6 (1.8) 125.6 (1.8) < 0.001
DBP (mmHg) 74.4 (1.2) 75.4 (1.2) 76.2 (1.2) 77.3 (1.2) 77.7 (1.2) < 0.001
Women 
(n = 2036)
WC (cm) 87.3 (0.5) 90.9 (0.5) 93.2 (0.5) 94.5 (0.5) 98.5 (0.5) < 0.001
TG (mmol/l) 1.9 (0.07) 2.1 (0.07) 2.1 (0.07) 2.2 (0.07) 2.4 (0.07) < 0.001
FPG (mmol/l) 6.6 (0.1) 6.4 (0.1) 6.5 (0.1) 6.5 (0.1) 6.6 (0.1) 0.2
HDL-C 
(mmol/l)
1.05 (0.02) 1.04 (0.02) 1.01 (0.02) 1.01 (0.02) 0.99 (0.02) 0.003
SBP (mmHg) 118.7 (1.2) 119.9 (1.2) 123 (1.2) 122.9 (1.2) 125.1 (1.2) < 0.001
DBP (mmHg) 74.9 (0.7) 76.1 (0.7) 77.2 (0.7) 77.2 (0.7) 78.6 (0.7) < 0.001
* Means were adjusted for age, baseline weight, smoking, physical activity, education level, medication use plus the corresponding variable at 
baseline; numbers in the parentheses present standard error.
† The gender-stratified percentage of weight change were grouped as follow: weight loss group (<-1.3% men, <-2.5% women); weight stable group 
(-1.3 to 1.3% men, -2.5 to 1.2% women); mild weight gain group (1.4 to 3.9% men, 1.3 to 3.9% women); moderate weight gain group (4 to 6.9% 
men, 4 to 7.6% women); large weight gain group (≥ 7% men, ≥ 7.7% women).
BMI: body mass index, WC: waist circumference, TG: triglyceride, FPG: fasting plasma glucose, SBP: systolic blood pressure, DBP: diastolic blood 
pressureBMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
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higher in women 23.1% (22.3–24) than in men 18.4%
(17.6–19.1), P < 0.001.
Table 2 showed means of the MetS parameters by gender-
stratified PWC quintiles after adjustment of previously
mentioned covariates. In both genders there was a strong
linear trend of weight gain and worsening of all MetS
parameters, except for the FPG level. Furthermore, the age
adjusted incidence (95% CI) of MetS by gender-stratified
PWC quintiles among the 2217 participants free of MetS
at baseline were as followed; weight loss group, 8.6%
(8.0–9.1) in men and 10.2% (9.6–10.8) in women;
weight stable group, 20% (16.2–17.7) in men and 12.2%
(11.5–12.8) in women; mild weight gain group, 17.1%
(16.3–17.8) in men and 23.4% (22.6–24.3) in women;
moderate weight gain group, 24.7% (23.8–25.5) in men
and 31.6% (30.7–32.5) in women; large weight gain
group, 22.7% (21.9–23.5) in men and 30.6% (29.7–31.5)
in women.
Table 3 and Figure 1 showed the adjusted RR (95% CI) of
the ATPIII defined MetS and its components according to
the weight change groups in men. Mild increase in weight
predicted high WC and high TG components, while mod-
erate increase was associated with high WC, high BP com-
ponents and incident MetS. In this gender, large weight
gain predicted MetS and all of its components except high
FPG. Weight loss had protective effect on the MetS with
the RR 0.5 (95% CI 0.3–1.0) and high WC component
with the RR 0.3 (95% CI 0.1–0.6).
The same analyses in women were shown in Table 4 and
Figure 1. In this gender group, increasing weight in any
category predicted MetS with the RR ranging from 2.5
(95% CI 1.4–4.3) for mild to 6.6 (95% CI 3.8–11.3) for
large weight gain. Mild weight gain showed association
with high WC and high BP components and moderate
weight gain predicted high WC and high TG components.
Large weight gain predicted all components except low
HDL-C, on the other hand weight loss found to be protec-
tive only against high WC component. Regarding the
effect of age on the relationship between weight gain and
MetS, especially in women, we divided women partici-
pants into those aged > 50 years and ≤ 50 years; the anal-
ysis according to this classification highlighted that in
women  ≤ 50 years the high BP component was not
affected by weight gain. However, in those older than 50
years the RRs of high WC and high BP considering weight
gain groups, were increased significantly (data not
shown).
As it is possible that using medication could affect the
association of weight change and MetS components, we
also performed analyses limited to subjects not treated for
hypertension, dyslipidemia or diabetes. Results were
unchanged after excluding subjects treated with medica-
tions (data not shown). Furthermore, when we adapted
the American Heart Association/National Heart, Lung,
and Blood Institute definition of MetS [19] [which con-
sidered medication treatment in MetS components classi-
fication] in place of original NCEP/ATP III, the results
remained unchanged (data not shown).
Table 3: Adjusted relative risk of ATPIII-defined metabolic syndrome components by weight change groups in men (n = 1431)*
Percentage of weight change
Loss group (<-1.3%) Stable group 
(-1.3 to 1.3%)
Mild gain group 
(1.4 to 3.9%)
Moderate gain group 
(4 to 6.9%)
Large gain group (≥ 7%)
High WC 0.3 (0.1–0.6) Reference 2.4 (1.3–4.4) 4.4 (2.4–8.0) 9.2 (4.8–17.5)
No. of subjects† 255 236 263 240 276
P value 0.001 0.005 < 0.001 < 0.001
High TG 0.8 (0.4–1.9) Reference 2.2 (1.1–4.5) 1.9 (0.9–3.8) 3.8 (1.9–7.7)
No. of subjects† 111 103 116 126 168
P value 0.7 0.03 0.08 < 0.001
Low HDL-C 0.8 (0.4–1.4) Reference 0.9 (0.5–1.6) 1.3 (0.7–2.5) 1.9 (1.0–3.4)
No. of subjects† 99 93 108 94 117
P value 0.4 0.8 0.3 0.04
High FPG 0.5 (0.2–1.2) Reference 1.4 (0.7–2.8) 1.2 (0.6–2.5) 1.3 (0.6–2.9)
No. of subjects† 236 234 265 248 281
P value 0.1 0.3 0.6 0.4
High BP 1.2 (0.6–2.7) Reference 1.8 (0.8–3.7) 2.7 (1.3–5.6) 3.4 (1.7–7.1)
No. of subjects† 155 160 175 176 225
P value 0.6 0.1 0.007 0.001
* Relative risks (95% CI) were adjusted for age, baseline weight, smoking, physical activity, education level and medication use.
† Only subjects free of mentioned component at baseline were entered in each analysis.
WC: waist circumference, TG: triglyceride, FPG: fasting plasma glucose, BP: blood pressureBMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
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Discussion
In this population based study of Iranian urban residents,
we showed that in men, more than a moderate increase in
weight (> 4% of the baseline weight) predicted incident
MetS, and weight reduction of at least 1.3% of initial body
weight plays a protective effect against this syndrome. In
women increase in weight, even a mild increase in a short
term follow-up (> 1.3% of the initial weight), was associ-
ated with an increased risk of incident MetS. In both gen-
ders weight loss was protective against high WC
component.
There was a 20.6% age-adjusted incident of MetS in our
study, which was accompanied by 3.8% incident Type 2
diabetes (FPG ≥ 7 mmol/l or medication use) (data not
shown). Onat et al in a representative population of Turk-
ish adults, with a high prevalence of MetS, showed inci-
dent cases of MetS in 225 (23%) men and 252 (≈25%)
women over a mean follow up of 5.9 years [20,21]. In a 4-
year cohort of 9785 Taiwanese adults, there was 17.5%
incidence of MetS in men versus 8.3% women, using
modified ATPIII definition [22]. Also in non diabetic
American Indians, who were free of MetS at baseline,
37.7% got the ATPIII defined syndrome at 10-year follow
up [23]. The European Lacidipine Study on Atherosclero-
sis showed 21.4% incident MetS in hypertensive subjects
aged 45–75 years, after 3.7 years follow-up [24].
The effect of weight change on MetS has been proposed to
be caused by insulin resistance; it has been also suggested
that insulin resistance may lead to MetS through accom-
modation of adiposity [25]. Weight gain was associated
with developing the insulin resistance syndrome in one
cross-sectional study on the Finish middle-aged men [8].
The same association of weight gain with incident ATPIII
defined MetS was found in the adult American population
[26]. Since the aim of this study was descriptive, we did
not make large multivariate analyses; so it would have
been difficult to interpret the higher incident of MetS in
women. However, in a multi center study in different eth-
nic groups, using signal detection analysis, the best predic-
tor of incident metabolic syndrome was waist
circumference [27]. Hence, regarding the high prevalence
of abdominal obesity in Iranian females [28]; the higher
relative risk for incident metabolic syndrome in this group
could be justifiable. The linear association of weight gain
with MetS parameters (except FPG) in our study was com-
parable to the Hiller et al. study, which showed the same
Adjusted relative risk of metabolic syndrome by weight change groups in both genders Figure 1
Adjusted relative risk of metabolic syndrome by weight change groups in both genders. From the total study pop-
ulation (1431 men and 2036 women), only 1037 men and 1180 women who were free of metabolic syndrome at baseline 
included in this logistic regression model. The model was adjusted for age, baseline weight, smoking, physical activity, education 
level and medication use. The gender-stratified percentage of weight change (PWC) was shown in the X axis, grouped as fol-
low: weight loss group [<-1.3% men (n = 191), <-2.5% women (n = 193)]; weight stable group [-1.3 to 1.3% men (n = 185), -2.5 
to 1.2% women (n = 204)]; mild weight gain group [1.4 to 3.9% men (n = 209), 1.3 to 3.9% women (n = 228)]; moderate weight 
gain group [4 to 6.9% men (n = 204), 4 to 7.6% women (n = 233)]; large weight gain group [= 7% men (n = 248), = 7.7% women 
(n = 322)]. The stable group was considered as reference. Relative risk (95% CI) for ATPIII defined metabolic syndrome 
according to PWC groups was shown in the Y axis.BMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
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association with each of the metabolic physiological con-
tinuous measures [6]. Nevertheless, we found a significant
decrease in BP, TG and HDL-C during this short term fol-
low up. However, favorable trends in TG and BP were not
enough to alleviate the risk of MetS in light of the increas-
ing trend in general and central obesity. Recently, in a
non-diabetic population, we showed that despite an
increasing trend in general and abdominal obesity, a favo-
rable trend in total cholesterol in both genders and TG in
men occurred, which was not related to the increasing
usage of lipid lowering drugs. However, this trend was
counterbalanced by unfavorable changes in HDL choles-
terol, which was found to decrease in both genders espe-
cially in men [15]. Similar declining trends in lipoprotein
level in light of the increasing trends in obesity were also
reported in U.S adult population [29].
Weight loss has been recognized to have beneficial effects
on several cardiovascular risk factors [30,31]. Some studies
have also shown that weight loss is followed by an
improvement of glucose tolerance and a reduced risk of
type 2 diabetes [32,33]. Villareal et al. have found that in
older obese adults the diet-induced weight loss (≈9% of ini-
tial body weight) during 6 months, could improve most of
the obesity-related CHD risk factors including high WC
[34]. Recently, Alhassan et al. reported that ≥ 7% reduction
in body weight has a beneficial impact on MetS variables
[35]. In our data analysis, weight loss of > 1.3% of initial
weight reduced risk of MetS [RR 0.5, 95%CI (0.3–1.0)] in
men; furthermore a mild weight loss decreased risk of the
high WC component in both genders.
In our study, weight gain increased the risk of high FPG in
women, but not in men. Considering the observational
nature of our study, delineating the reason for this diver-
gence between genders regarding weight gain and risk of
abnormal glucose metabolism was difficult. However, in
Turkish adults with a similar prevalence of MetS, women
with normal glucose metabolism were more prone to inci-
dent dibetes than men [36]. Furthermore, in a recent pop-
ulation based study from Denmark, women who had
gained and sustained considerable weight were more sus-
ceptible to development of new onset diabetes [37]. Dur-
ing the short term follow-up in our study, attained BMI
(in phase 2) and BMI changes were more marked in
women than men (mean of BMI change: 0.99 vs. 0.66 kg/
m2; P < 0.001, respectively). On the other hand, body
weight is a stronger predictor of Type 2 diabetes than
physical activity, considering the finding that physical
activity was significantly lower in Iranian women than
men [38,39]. Hence, the higher prevalence of diabetes
and abnormal glucose metabolism (i.e. impaired fasting
glucose or impaired glucose tolerance) in Iranian women
than in men was justifiable [40].
Overall we also found the association of high BP compo-
nent with weight gain in both genders. Furthermore, the
synergistic contribution of insulin resistance and meno-
pause to components of the metabolic syndrome was
reported recently with SBP, DBP and WC [41], this may
explain the accelerated impact of weight gain on abdomi-
nal obesity and blood pressure among women aged ≥ 50
in the current study. In a cohort study of adult men, an
Table 4: Adjusted relative risk of ATPIII-defined metabolic syndrome components by weight change groups in women (n = 2036)*
Percentage of weight change
Metabolic syndrome 
components
Loss group (<-2.5%) Stable group 
(-2.5 to 1.2%)
Mild gain group 
(1.3 to 3.9%)
Moderate gain group 
(4 to 7.6%)
Large gain group (≥ 
7.7%)
High WC 0.3 (0.2–0.7) Reference 1.9 (1.1–3.2) 2.8 (1.6–5.0) 7.3 (4.1–13.0)
No. of subjects † 149 162 206 192 286
P value .003 .03 < 0.001 < 0.001
High TG 0.7 (0.4–1.2) Reference 1.2 (0.7–2.1) 2.1 (1.3–3.6) 2.7 (1.7–4.4)
No. of subjects † 173 201 202 204 294
P value 0.2 0.5 0.003 < 0.001
Low HDL-C 0.7 (0.4–1.2) Reference 0.9 (0.5–1.6) 1.1 (0.6–2.0) 1.5 (0.8–2.7)
No. of subjects † 101 107 96 99 119
P value 0.2 0.7 0.7 0.2
High FPG 0.7 (0.3–1.6) Reference 1.6 (0.8–3.1) 1.5 (0.7–2.9) 4.3 (2.2–8.2)
No. of subjects † 307 339 340 358 396
P value 0.4 0.1 0.3 < 0.001
High BP 0.9 (0.5–1.8) Reference 2 (1.1–3.5) 1.3 (0.7–2.5) 2.1 (1.1–3.7)
No. of subjects † 244 240 256 263 338
P value 0.9 0.02 0.3 0.01
* Relative risks (95% CI) were adjusted for age, baseline weight, smoking, physical activity, education level and medication use.
† Only subjects free of mentioned component at baseline were entered in each analysis.
WC: waist circumference, TG: triglyceride, FPG: fasting plasma glucose, BP: blood pressureBMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
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increased in BMI was found to be associated with an
increased risk of hypertension and weight loss did not
affect risk of hypertension significantly [9].
The results of our study are difficult to compare with other
studies conducted on the association of weight change
and cardiovascular risk factors because of differences in
the time period between the two weight measures, the
length of follow up, and how weight change is expressed.
There are some other points that should be considered
when examining the results of our study. First, about 43%
of the baseline participants were excluded from cohort
analysis because of loss to follow-up or missing data. This
group was healthier in their baseline characteristic assess-
ments; hence we may have overestimated the incidence of
metabolic syndrome in the general population. Second,
our findings were derived from an observational prospec-
tive study; so we did not have information on whether
weight loss in this cohort was intentional or uninten-
tional. Finally it must be emphasized that the conclusions
drawn from this study were determined in Middle East
Caucasian residents in the capital city of Iran and further
studies should be conducted to determine whether our
findings can apply to other populations of this region.
Among the existing studies addressing the relationship
between weight change and MetS, only a few have ana-
lyzed their data on the longitudinal effects of weight
change adjusting for confounding variables [7,10]. We
were also able to adjust for several important confound-
ing variables and to explore the effects of different weight
change groups in separate genders. Moreover, we used
anthropometric variables that were directly measured by
trained medical professionals rather than self-reported or
self-measured anthropometrics.
Conclusion
In this population based cohort study we found a strong
positive association of weight gain and increased risk of
MetS, especially in women. Furthermore, weight loss had
protective effects on the incident MetS in men and high
WC component in both genders. Along with previous
findings, these data suggest that promoting weight control
in the Iranian population is crucial to prevent increasing
risk of MetS.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AZ participated in conception and design of the study,
performing the statistical analysis and drafting the manu-
script. FH participated in the conception and design of the
study, drafting the manuscript, critical revision and its
final approval. PS participated in the statistical analysis of
the study. FA participated in its design and coordination.
All authors read and approved the final manuscript.
Acknowledgements
This study was supported by Grant No. 121 from the National Research 
Council of the Islamic Republic of Iran. We express appreciation to Dr. 
Mohammad Reza Bozorgmanesh, Ms. Nilufar Shiva and the participants of 
district 13, Tehran, for their enthusiastic support in this study.
References
1. Seidell JC: Obesity: a growing problem.  Acta Paediatr Suppl 1999,
88:46-50.
2. Shaper AG, Wannamethee SG, Walker M: Body weight: implica-
tions for the prevention of coronary heart disease, stroke,
and diabetes mellitus in a cohort study of middle aged men.
BMJ 1997, 314:1311-7.
3. Seidell JC, Verschuren WM, van Leer EM, Kromhout D: Over-
weight, underweight, and mortality. A prospective study of
48,287 men and women.  Arch Intern Med 1996, 156:958-63.
4. Washio M, Hayashi R, Fukuoka Heart Study Group: Past history of
obesity (overweight by WHO criteria) is associated with an
increased risk of nonfatal acute myocardial infarction: a
case-control study in Japan.  Circ J 2004, 68:41-6.
5. Su HY, Sheu WH, Chin HM, Jeng CY, Chen YD, Reaven GM: Effect
of weight loss on blood pressure and insulin resistance in nor-
motensive and hypertensive obese individuals.  Am J Hyperten
1995, 8:1067-71.
6. Hillier TA, Fagot-Campagna A, Eschwège E, Vol S, Cailleau M, Balkau
B: the D.E.S.I.R. Study group. Weight change and changes in
the metabolic syndrome as the French population moves
towards overweight: the D.E.S.I.R. cohort.  Int J Epidemiol 2006,
35:190-6.
7. Ferrannini E, Haffner SM, Mitchell BD, Stern MP: Hyperinsulinae-
mia: the key feature of a cardiovascular and metabolic syn-
drome.  Diabetologia 1991, 34:416-22.
8. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan
GA, Salonen JT: Weight gain and the risk of developing insulin
resistance syndrome.  Diabetes Care 1998, 21:1637-43.
9. Ishikawa-Takata K, Ohta T, Moritaki K, Gotou T, Inoue S: Obesity,
weight change and risks for hypertension, diabetes and
hypercholesterolemia in Japanese men.  Eur J Clin Nutr 2002,
56:601-7.
10. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM:
Impact of weight loss on the metabolic syndrome.  Diabetes
Obes Metab 2002, 4:407-14.
11. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhai-
lidis DP, Elisaf MS: Effect of orlistat, micronised fenofibrate and
their combination on metabolic parameters in overweight
and obese patients with the metabolic syndrome: the
FenOrli study.  Curr Med Res Opin 2005, 21:1997-2006.
12. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina
S, Fowler S, Diabetes Prevention Program Research Group: The
effect of metformin and intensive lifestyle intervention on
the metabolic syndrome: the Diabetes Prevention Program
randomized trial.  Ann Intern Med 2005, 142:611-9.
13. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan
GA, Salonen JT: The effect of sex, age and race on estimating
percentage body fat from body mass index: The Heritage
Family Study.  Int J Obes Relat Metab Disord 2002, 26:789-96.
14. Lahmann PH, Lissner L, Gullberg B, Berglund G: A prospective
study of adiposity and all-cause mortality: the Malmö Diet
and Cancer Study.  Obes Res 2002, 10:361-9.
15. PJ.Bozorgmanesh MR, Hadaegh F, Padyab M, Mehrabi Y, Azizi F:
Temporal changes in anthropometric parameters and lipid
profile according to body mass index among an adult Iranian
urban population.  Ann Nutr Metab 2008, 53:13-22.
16. Zabetian A, Hadaegh F, Azizi F: Prevalence of metabolic syn-
drome in Iranian adult population, concordance between
the IDF with the ATPIII and the WHO definitions.  Diabetes
Res Clin Pract 2007, 77:251-7.
17. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M,
Ghanbili J, Ghanbarian A, Mehrabi Y, Saadat N, Salehi P, Mortazavi N,
Heydarian P, Sarbazi N, Allahverdian S, Saadati N, Ainy E, Moeini S:Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Public Health 2009, 9:138 http://www.biomedcentral.com/1471-2458/9/138
Page 9 of 9
(page number not for citation purposes)
Cardiovascular risk factors in an Iranian urban population:
Tehran lipid and glucose study (phase 1).  Soz Praventivmed
2002, 47:408-26.
18. Expert Panel on Detection, Evaluation and Treatment of High Blood
Cholesterol in Adults: Executive Summary of The Third Report
of The National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, And Treatment of
High Blood Cholesterol In Adults (Adult Treatment Panel
III).  JAMA 2001, 285:2486-97.
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin
BA, et al.: Diagnosis and management of the metabolic syn-
drome: an American Heart Association/National Heart,
Lung, and Blood Institute Scientific Statement.  Circulation
2005, 112:2735-52.
20. Onat A, Sari I, Hergenç G, Yazici M, Uyarel H, Can G, Sansoy V:
Determinants and definition of abdominal obesity as related
to risk of diabetes, metabolic syndrome and coronary dis-
ease in Turkish men: a prospective cohort study.  Atherosclero-
sis 2007, 191:182-90.
21. Onat A, Sari I, Hergenç G, Yazici M, Uyarel H, Can G, Sansoy V: Pre-
dictors of abdominal obesity and high susceptibility of cardi-
ometabolic risk to its increments among Turkish women: a
prospective population-based study.  Metabolism 2007,
56:348-56.
22. Yang FY, Wahlqvist ML, Lee MS: Body mass index (BMI) as a
major factor in the incidence of the metabolic syndrome and
its constituents in unaffected Taiwanese from 1998 to 2002.
Asia Pac J Clin Nutr 2008, 17:339-51.
23. Lucove J, Vupputuri S, Heiss G, North K, Russell M: Metabolic syn-
drome and the development of CKD in American Indians:
the Strong Heart Study.  Am J Kidney Dis 2008, 51:21-8.
24. Zanchetti A, Hennig M, Baurecht H, Tang R, Cuspidi C, Carugo S,
Mancia G: Prevalence and incidence of the metabolic syn-
drome in the European Lacidipine Study on Atherosclerosis
(ELSA) and its relation with carotid intima-media thickness.
J Hypertens 2007, 25:2463-70.
25. Zhang H, Tamakoshi K, Yatsuya H, Murata C, Wada K, Otsuka R,
Nagasawa N, Ishikawa M, Sugiura K, Matsushita K, Hori Y, Kondo T,
Toyoshima H: Long-term body weight fluctuation is associated
with metabolic syndrome independent of current body mass
index among Japanese men.  Circ J 2005, 69:13-8.
26. Gregg EW, Gerzoff RB, Thompson TJ, Williamson DF: Intentional
weight loss and death in overweight and obese U.S. adults 35
years of age and older.  Ann Intern Med 2003, 138:383-9.
27. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haff-
ner SM, Wagenknecht L, Insulin Resistance Atherosclerosis Study:
Predictors of the incident metabolic syndrome in adults: the
Insulin Resistance Atherosclerosis Study.  Diabetes Care 2004,
27:788-93.
28. Zabetian A, Hadaegh F, Azizi F: Prevalence of metabolic syn-
drome in Iranian adult population, concordance between
the IDF with the ATPIII and the WHO definitions.  Diabetes
Res Clin Pract 2007, 77:251-7.
29. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M,
Grundy SM, Johnson CL: Trends in serum lipids and lipopro-
teins of adults, 1960–2002.  JAMA 2005, 294:1773-81.
30. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C,
Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan
M, Wedel H, Swedish Obese Subjects Study Scientific Group: Life-
style, diabetes, and cardiovascular risk factors 10 years after
bariatric surgery.  N Engl J Med 2004, 351:2683-93.
31. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R,
Giugliano D: Effect of weight loss and lifestyle changes on vas-
cular inflammatory markers in obese women: a randomized
trial.  JAMA 2003, 289:1799-804.
32. Moore LL, Visioni AJ, Wilson PW, D'Agostino RB, Finkle WD, Ellison
RC:  Can sustained weight loss in overweight individuals
reduce the risk of diabetes mellitus?  Epidemiology 2000,
11:269-73.
33. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H,
Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A,
Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study
Group: Prevention of type 2 diabetes mellitus by changes in
lifestyle among subjects with impaired glucose tolerance.  N
Engl J Med 2001, 344:1343-50.
34. Villareal DT, Miller BV 3rd, Banks M, Fontana L, Sinacore DR, Klein S:
Effect of lifestyle intervention on metabolic coronary heart
disease risk factors in obese older adults.  Am J Clin Nutr 2006,
84:1317-23.
35. Alhassan S, Kiazand A, Balise RR, King AC, Reaven GM, Gardner CD:
Metabolic syndrome: do clinical criteria identify similar indi-
viduals among overweight premenopausal women?  Metabo-
lism 2008, 57:49-56.
36. Onat A, Hergenç G, Keles ¸ I, Doğan Y, Türkmen S, Sansoy V: Sex dif-
ference in development of diabetes and cardiovascular dis-
ease on the way from obesity and metabolic syndrome.
Metabolism 2005, 54:800-8.
37. de Fine Olivarius N, Richelsen B, Siersma V, Andreasen AH, Beck-
Nielsen H: Weight history of patients with newly diagnosed
Type 2 diabetes.  Diabet Med 2008, 25:933-41.
38. Janghorbani M, Amini M, Willett WC, Mehdi Gouya M, Delavari A,
Alikhani S, Mahdavi A: First nationwide survey of prevalence of
overweight, underweight, and abdominal obesity in Iranian
adults.  Obesity 2007, 15:2797-808.
39. Hu G, Lindström J, Valle TT, Eriksson JG, Jousilahti P, Silventoinen K,
Qiao Q, Tuomilehto J: Physical activity, body mass index, and
risk of type 2 diabetes in patients with normal or impaired
glucose regulation.  Arch Intern Med 2004, 164:892-6.
40. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi
F: High prevalence of undiagnosed diabetes and abnormal
glucose tolerance in the Iranian urban population: Tehran
Lipid and Glucose Study.  BMC Public Health 2008, 24(8):176.
41. Lin KC, Tsai ST, Kuo SC, Tsay SL, Chou P: Interrelationship
between insulin resistance and menopause on the metabolic
syndrome and its individual component among nondiabetic
women in the kinmen study.  Am J Med Sci 2007, 333:208-14.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2458/9/138/pre
pub